Shanghai Haihe Pharmaceutical Co., Ltd has entered into a licensing agreement with Taiho Pharmaceutical Co., Ltd, granting the Japanese company exclusive rights to develop, manufacture, and commercialize glumetinib, a MET-targeted tyrosine kinase inhibitor (TKI), in Japan and other Asian countries (excluding China) and Oceania. Haihe has already submitted a market filing for the drug in Japan.
Under the terms of the agreement, Taiho will provide Haihe with an undisclosed upfront payment, along with milestone payments and sales royalties.
Glumetinib received approval in March 2023 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET14 exon skipping in China. The drug was subsequently filed for marketing in China in September 2023, targeting locally advanced or metastatic NSCLC with MET14 exon mutations.- Flcube.com
